HMGCR在雌激素受体阳性乳腺癌患者中的表达及意义

Expression and significance of HMGCR protein in breast cancer patients with estrogen receptor positive

目的探讨雌激素受体阳性乳腺癌患者肿瘤组织3-羟基-3-甲基戊二酰辅酶A还原酶(3-hydroxy-3-methylglutaryl-coenzyme-A reductase,HMGCR)表达及对预后的影响。方法雌激素受体阳性乳腺癌患者131例,取手术切除肿瘤组织(乳腺癌组)及癌旁正常组织(癌旁组),采用免疫组织化学法检测HMGCR蛋白阳性表达率,分析HMGCR蛋白阳性表达与临床病理特征的关系,随访观察HMGCR蛋白阳性表达者与阴性表达者无进展生存期。结果乳腺癌组HMGCR蛋白阳性表达率(71.8%)高于癌旁组(28.2%)(P<0.05)。有腋窝淋巴结转移者HMGCR蛋白阳性表达率(75.7%)高于无腋窝淋巴结转移者(66.7%)(P<0.05),不同年龄、体质量指数、肿瘤直径、TNM分期等患者HMGCR蛋白阳性表达率比较差异无统计学意义(P>0.05)。随访(54.7±6.0)个月,HMGCR蛋白阳性表达者中位无进展生存期(52.4个月)较HMGCR蛋白阴性表达者(55.1个月)短(P<0.05)。结论HMGCR蛋白阳性表达可促进雌激素受体阳性乳腺癌转移,缩短无进展生存期。

Objective To investigate the expression of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase(HMGCR)in cancer tissues in breast cancer patients with estrogen receptor positive and its influence on the prognosis.Methods The positive expression rate of HMGCR protein was detected by immunohistochemistry in the resected tumor tissues(breast cancer group)and adjacent normal tissues(normal group)in 131breast cancer patients with estrogen receptor positive.The relationship between the positive expression of HMGCR protein and clinical characteristics was analyzed.The progression-free survival was followed up and compared between the patients with HMGCR protein positive and negative.Results The expression of HMGCR protein was significantly higher in breast cancer group(71.8%)than that in normal group(28.2%)(P<0.05),and in patients with axillary lymph node metastasis(75.7%)than that in patients without axillary lymph node metastasis(66.7%)(P<0.05).There were no significant differences in the positive expression rates of HMGCR in patients with different age,body mass index and tumor diameter(P>0.05).All patients were followed up for(54.7±6.0)months.The median progression-free survival was shorter in HMGCR positive patients(52.4months)than that in HMGCR negative patients(55.1months)(P<0.05).Conclusion The positive expression of HMGCR protein can promote the metastasis of estrogen receptor positive breast cancer patients and shorten the progression-free survival.